logo-loader
viewGenprex, Inc.

Full interview: Genprex gets FDA Fast Track for its Oncoprex combination therapy, raises $8M

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has been granted Fast Track Designation by the FDA for its Oncoprex immunogene therapy to treat lung cancer. Varner says the FDA validation is important, and gives the company more opportunities to meet with the FDA and facilitate the process of drug approval.

Quick facts: Genprex, Inc.

Price: 5.33 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $148.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CEO Rodney Varner sees newly licensed therapy as an...

 (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a therapy that could have the potential to treat Type 1 and Type 2 diabetes. Varner says the newly licensed therapy was an 'opportunity we...

1 week, 3 days ago

2 min read